Semaglutide implant - Vivani Medical
Alternative Names: NPM-133; NPM-139; Semaglutide NanoPortal implant - Vivani MedicalLatest Information Update: 27 Nov 2025
At a glance
- Originator Nano Precision Medical
- Developer Vivani Medical
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 13 Nov 2025 Preclinical trials in Type 2 diabetes mellitus in USA (SC) prior to November 2025 (Vivani Medical pipeline; November 2025)
- 04 Sep 2025 Vivani Medical plans to initiate a phase I trial for Obesity in the first half of 2026 (SC, Implant)
- 04 Sep 2025 Vivani Medical plans to initiate a phase II trial for Obesity (SC, Implant)